Biotransformation is a key process that can greatly influence the bioaccumulation potential and toxicity of organic compounds. In this study, biotransformation of seven frequently used azole fungicides (triazoles: cyproconazole, epoxiconazole, fluconazole, propiconazole, tebuconazole and imidazoles: ketoconazole, prochloraz) was investigated in the aquatic invertebrate Gammarus pulex in a 24 h exposure experiment. Additionally, temporal trends of the whole body internal concentrations of epoxiconazole, prochloraz, and their respective biotransformation products (BTPs) were studied to gain insight into toxicokinetic processes such as uptake, elimination and biotransformation. By the use of high resolution tandem mass spectrometry in total 37 BTPs were identified. Between one (ketoconazole) and six (epoxiconazole) BTPs were identified per parent compound except for prochloraz, which showed extensive biotransformation reactions with 18 BTPs detected that were mainly formed through ring cleavage or ring loss. In general, most BTPs were formed by oxidation and conjugation reactions. Ring loss or ring cleavage was only observed for the imidazoles as expected from the general mechanism of oxidative ring openings of imidazoles, likely affecting the bioactivity of these BTPs. Overall, internal concentrations of BTPs were up to 3 orders of magnitude lower than that of the corresponding parent compound. Thus, biotransformation did not dominate toxicokinetics and only played a minor role in elimination of the respective parent compound, with the exception of prochloraz.

This study presents a nontarget approach to detect discharges from pharmaceutical production in municipal wastewater treatment plant (WWTP) effluents and to estimate their relevance on the total emissions. Daily composite samples were collected for 3 months at two WWTPs in Switzerland, measured using liquid chromatography high-resolution mass spectrometry, and time series were generated for all features detected. The extent of intensity variation in the time series was used to differentiate relatively constant domestic inputs from highly fluctuating industrial emissions. We show that an intensity variation threshold of 10 correctly classifies compounds of known origin and reveals clear differences between the two WWTPs. At the WWTP receiving wastewater from a pharmaceutical manufacturing site, (i) 10 times as many potential industrial emissions were detected as compared to the WWTP receiving purely domestic wastewater; (ii) for 11 pharmaceuticals peak concentrations, >10 g/L and up to 214 g/L were quantified, which are clearly above typical municipal wastewater concentrations; and (iii) a pharmaceutical not authorized in Switzerland was identified. Signatures of potential industrial emissions were even traceable at the downstream Rhine monitoring station at a >4000-fold dilution. Several of them occurred repeatedly, suggesting that they were linked to regular production, not to accidents. Our results demonstrate that small wastewater volumes from a single industry not only left a clear signature in the effluents of the respective WWTP but also influenced the water quality of one of Europe's most important river systems. Overall, these findings indicate that pharmaceutical production is a relevant emission source even in highly developed countries with a strong focus on water quality, such as Switzerland.

To optimize removal of organic micropollutants from the water cycle, understanding the processes during activated sludge treatment is essential. In this study, we hypothesize that aliphatic amines, which are highly abundant among organic micropollutants, are partly removed from the water phase in activated sludge through ion trapping in protozoa. In ion trapping, which has been extensively investigated in medical research, the neutral species of amine-containing compounds diffuse through the cell membrane and further into acidic vesicles present in eukaryotic cells such as protozoa. There they become trapped because diffusion of the positively charged species formed in the acidic vesicles is strongly hindered. We tested our hypothesis with two experiments. First, we studied the distribution of the fluorescent amine acridine orange in activated sludge by confocal fluorescence imaging. We observed intense fluorescence in distinct compartments of the protozoa, but not in the bacterial biomass. Second, we investigated the distribution of 12 amine-containing and eight control micropollutants in both regular activated sludge and sludge where the protozoa had been inactivated. In contrast to most control compounds, the amine-containing micropollutants displayed a distinctly different behavior in the noninhibited sludge compared to the inhibited one: (i) more removal from the liquid phase; (ii) deviation from first-order kinetics for the removal from the liquid phase; and (iii) higher amounts in the solid phase. These results provide strong evidence that ion trapping in protozoa occurs and that it is an important removal mechanism for amine-containing micropollutants in batch experiments with activated sludge that has so far gone unnoticed. We expect that our findings will trigger further investigations on the importance of this process in full-scale wastewater treatment systems, including its relevance for accumulation of ammonium.

No abstract

In this work, emissions of active pharmaceutical ingredients (APIs) from formulating pharmaceutical industries (FPIs) were investigated for the first time based on detailed production information and compared to overall API emissions in wastewater treatment plant (WWTP) effluents. At two municipal WWTPs, both receiving wastewater from several FPIs, two months' daily effluent samples were collected and measured using liquid chromatography high-resolution mass spectrometry (LC-HRMS). Thirty-three APIs formulated during the sampling period as well as >120 organic contaminants commonly present in WWTP effluents were quantified. On the basis of their time patterns and manufacturing data, industrial contributions were found for 22 of 26 APIs (85%) detected in the samples and processed by the FPIs. API emissions from FPIs led to daily concentration increases of up to 300-fold, despite pretreatment of the industrial wastewater. However, emissions from FPIs seemed to depend on the type of formulating activity, with granulation and mixing being most prone to API losses. Losses from FPIs were responsible for the highest concentrations and for up to 60% of the daily total API emissions measured. Furthermore, screening for suspects in LC-HRMS data resulted in the detection of unexpected emissions from FPIs, demonstrating the value of these data to comprehensively assess industrial API losses. Overall, this study showed that FPIs were relevant contributors of APIs emitted in the WWTP effluents, although only a minor fraction (<1%) of the total processed API quantity was lost to the wastewater, and despite the small percentage (<5%) of FPI wastewater compared to the total wastewater flow.

No abstract

Despite their strict environmental regulations and state-of-the-art wastewater treatment infrastructure, chemical and pharmaceutical industries in Switzerland leave a clear footprint in treated wastewater that is released into the open environment.

Despite their strict environmental regulations and state-of-the-art wastewater treatment infrastructure, chemical and pharmaceutical industries in Switzerland leave a clear footprint in treated wastewater that is released into the open environment.